| Descriptor English: | Zalcitabine | ||||||
| Descriptor Spanish: |
Zalcitabina
| ||||||
| Descriptor Portuguese: | Zalcitabina | ||||||
| Descriptor French: | Zalcitabine | ||||||
| Entry term(s): |
2',3' Dideoxycytidine 2',3'-Dideoxycytidine Dideoxycytidine HIVID Roche Hivid NSC 606170 NSC-606170 NSC606170 ddC (Antiviral) |
||||||
| Tree number(s): |
D03.383.742.680.245.500.950 D13.570.230.329.950 D13.570.230.500.925 D13.570.685.245.500.950 |
||||||
| RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D016047 | ||||||
| Scope note: | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. |
||||||
| Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
| Pharm Action: |
Antimetabolites Reverse Transcriptase Inhibitors Anti-HIV Agents |
||||||
| Registry Number: | 6L3XT8CB3I | ||||||
| CAS Type 1 Name: | Cytidine, 2',3'-dideoxy- | ||||||
| Previous Indexing: |
Deoxycytidine/analogs & derivatives (1986-1989) Dideoxynucleosides (1989) |
||||||
| Public MeSH Note: | 94; was DIDEOXYCYTIDINE 1990-93 |
||||||
| Online Note: | use ZALCITABINE to search DIDEOXYCYTIDINE 1990-93 |
||||||
| History Note: | 94; was DIDEOXYCYTIDINE 1990-93 |
||||||
| DeCS ID: | 31821 | ||||||
| Unique ID: | D016047 | ||||||
| Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
| Date Established: | 1990/01/01 | ||||||
| Date of Entry: | 1989/07/14 | ||||||
| Revision Date: | 2017/05/24 |
-
-
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds
|
|
Zalcitabine
- Preferred
NSC-606170
- Narrower
Hivid
- Narrower
| Concept UI |
M0024532 |
| Scope note | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. |
| Preferred term | Zalcitabine |
| Entry term(s) |
2',3' Dideoxycytidine 2',3'-Dideoxycytidine Dideoxycytidine ddC (Antiviral) |
| Concept UI |
M0332662 |
| Preferred term | NSC-606170 |
| Entry term(s) |
NSC 606170 NSC606170 |
| Concept UI |
M0024533 |
| Preferred term | Hivid |
| Entry term(s) |
HIVID Roche |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey
